Pfizer’s Shares Fall As It Leaves Forecast For COVID Products Unchanged

On Thursday, Pfizer Inc. reported its quarterly results but did not change the sales forecast for the year of its COVID-19 antiviral treatment and vaccine.

This saw the company’s shares record losses of 5% before they managed to trim some of them.

Pfizer report

Even though the sales of Pfizer’s Paxlovid antiviral pills for the second quarter were significantly higher than expected, the US drugmaker kept its forecast of COVID products for the full year at $54 billion.

This prompted concerns about the long-term growth prospects of the company. Wall Street estimates had put the sales of Paxlovid a full $1 billion below the actual results.

Pfizer disclosed that the second quarter sales for the antiviral treatment were $8.1 billion, as demand for the treatment rose with a rise in cases.

US President Joe Biden also recently took a course on the drug because of his bout with COVID.

The drugmaker also did not change its overall forecast and chose to keep it between $98 billion and $102 billion because of a strong dollar.

Sales performance

There has been an unprecedented increase in the sales of Pfizer Inc., after it rolled out its COVID-19 vaccine globally, which it had developed with German firm BioNTech.

However, since the previous year, there has been a decline in the sales figure. Analysts seem to be divided over the durability of the Paxlovid treatment as well as the vaccine, considering that the urgency of the pandemic is waning.

Market analysts said that the long-term sustainability of the business is debatable and it will be essential for Pfizer to develop new drugs in order for it to be able to surpass expectations.

The company has been relying on sales of the booster doses of its vaccine to boost demand in the next couple of years, including a vaccine version tailed for the Omicron variant expected in the fall.

Vaccine deal

Last month, Pfizer Inc. and BioNTech signed a deal with the US government worth $3.2 billion for about 105 million doses of the COVID-19 vaccine.

This also includes the supply of the booster that has been adapted for the Omicron variant, which is yet to get regulatory clearance.

The sales for the second quarter overall were $27.74 billion, which were higher than the estimates of $25.74 billion from analysts.

Market analysts said that if COVID is excluded from the picture, then it appears to be less rosy for the company.

This is because sales of other drugs and treatments by Pfizer, such as Xeljanz for arthritis and Ibrance for breast cancer, were well below estimates.

The numbers stood at $430 million and $1.32 billion, respectively. There was a 13% increase in the sales of the COVID-19 vaccine, which saw them reach $8.85 billion.

The second quarter profit of Pfizer Inc. climbed to $9.91 billion, as opposed to a year ago when it had been $5.56 billion. The company’s shares recorded a decline of 1.2% to trade at $50.93.

Leave a Reply

Your email address will not be published.

Related

South Korea Implements Guidelines for Security Token Regulation

Adoption of Blockchain-based IDs Phasing Out Physical IDs Security Token Regulation South Korea’s Financial Services Commission (FSC) published new guidelines on Monday stating that FSC will regulate digital securities or blockchain-based tokenized assets according to the capital market rules. The highly anticipated regulations are to institutionalize with the legislators of the country’s National assembly laying […]

Post-Fed Analysis on Altcoins and Other Cryptos

Cardano’s bullish rise in the past days Bitcoin prices fallout Impact of the NFP Report on the cryptocurrency Cardano’s Bullish Rise Small coins have gained after the Central banks in Europe, and the UK decided to ease the hiking of high-interest rates.  Currencies such as Cardano increased in New York with gains above 2%, extending […]

What is Copy Trade and How It Works?

Copy Trade Intro Copy trade or copy trading is a type of trading in which one trader (the “follower”) automatically copies the trades of another trader (the “leader”). This is done through a copy trading platform, which connects the follower and leader and allows the follower to automatically copy the leader’s trades in real-time. How […]